Research Articles | Page 37 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Rethinking clinical trial endpoints in myelodysplastic syndromes. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) Jul 2020 Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Dec 2023 Leukemia Aplastic Anemia
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index Sep 2020 Leukemia Myelodysplastic Syndromes (MDS)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Eat and be healthy: nutritional status in myelodysplastic syndromes Jul 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Mar 2025 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy Oct 2020 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study Nov 2024 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents Oct 2019 Leukemia & Lymphoma Myelodysplastic Syndromes (MDS)